Novartis agreed to acquire an experimental breast-cancer drug from Synnovation Therapeutics for up to $3 billion.
: Large firms like Eli Lilly and Novartis are racing to replace revenue from older drugs that are nearing patent expiration. buy cancer
: Rated as a Strong Buy by Piper Sandler for its work in overcoming treatment resistance. buy cancer
Novartis to Buy Breast-Cancer Drug From Synnovation ... - WSJ buy cancer